Abstract: The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
Abstract: The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.
Type:
Grant
Filed:
March 24, 2021
Date of Patent:
March 1, 2022
Assignee:
ELLODI PHARMACEUTICALS, L.P.
Inventors:
Michael A. Gosselin, Jin-Wang Lai, Gopi M. Venkatesh
Abstract: The present invention relates to prevention and/or treatment of diseases or disorders associated with a damaged or leaky vasculature in a subject. The present invention provides for methods, combinations and pharmaceutical compositions for preventing and/or treating a disease or disorder associated with a damaged or leaky vasculature in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, an outer surface comprising a cellular membrane derived from a platelet; and optionally an agent for preventing, treating, diagnosing, or prognosing the disease or disorder and/or monitoring prevention or treatment of the disease or disorder. Exemplary diseases or disorders include hemorrhage (bleeding), cardiovascular diseases or disorders, diseases or disorders associated with narrowing of a blood vessel, tumors or cancers.
Type:
Grant
Filed:
June 7, 2016
Date of Patent:
February 8, 2022
Assignee:
The Regents of the University of California
Inventors:
Liangfang Zhang, Che-Ming Jack Hu, Ronnie H. Fang, Brian T. Luk, Kuei-Chun Wang, Shu Chien
Abstract: The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.
Abstract: The invention relates in particular to an injectable sclerosant drug foam comprising: (i) a matrix; (ii) at least one fluid; (iii) at least one sclerosant drug; (iv) a medical gas or medical gas mixture acceptable for intravenous use, (v) wherein said matrix has physical properties, which are comparable to denatured blood, wherein the denatured blood is obtainable from a fresh human venous whole blood sample of 1 ml volume, which is heated in a cylindrical polyethylene container with 3 mm inner diameter and 3.4 mm outer diameter for about 0.5 min. to about 10 min. at a temperature of about between 70° C. and 100° C. and/or (vii) said level of denaturation is defined by the change of red-colored hemoglobin to brown as an indicator, wherein Fe2+ is reduced to Fe3+ in the hemoglobin complex to a degree of at least 80%, preferably 90% and even more preferably 95%.
Type:
Grant
Filed:
May 21, 2019
Date of Patent:
January 25, 2022
Assignee:
SWISS VX VENETHERAPIE UND FORSCHUNG GMBH
Abstract: The present invention relates to prevention and/or treatment of infection by a platelet-targeting microbe in a subject. The present invention provides for methods, combinations and pharmaceutical compositions for preventing and/or treating (and/or related uses) infection by a platelet-targeting microbe in a subject, using, inter alia, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, b) an outer surface comprising a cellular membrane derived from a platelet; and optionally c) an agent for preventing said infection, treating said infection, diagnosing said infection, prognosing said infection and/or monitoring prevention or treatment of said infection. Exemplary platelet-targeting infections include infections by a bacterium, a virus, a fungus and/or a parasite.
Type:
Grant
Filed:
June 7, 2016
Date of Patent:
January 18, 2022
Assignee:
The Regents of the University of California
Inventors:
Liangfang Zhang, Che-Ming Jack Hu, Ronnie H. Fang, Brian T. Luk, Soracha Kun Thamphiwatana
Abstract: The present invention is related to a composition comprising phytic acid or a phytate salt, magnesium in the form of salt, hydroxide or oxide and optionally at least one polyphenol. These components may be in isolated form or be part of an enriched plant extract. The invention is also related to the use of this composition for the treatment of renal lithiasis, preferably calcium or calcium oxalate lithiasis, either in the form of a medicament, a nutraceutical or functional food or food supplement.
Type:
Grant
Filed:
April 14, 2015
Date of Patent:
January 4, 2022
Assignee:
UNIVERSITAT DE LES ILLES BALEARS
Inventors:
Félix Grases Freixedas, Antonia Costa Bauzá, Rafael María Prieto Almirall, Adrián Rodríguez Rodríguez
Abstract: The present invention relates to a novel cosmetic or dermatological composition for topical or oral use, comprising at least one passionflower extract, at least edelweiss callus cells, and at least one physiologically acceptable support, to a non-therapeutic cosmetic skin treatment process using such a cosmetic composition, and also to the non-therapeutic use of such a cosmetic composition for protecting the skin against environmental attack, preventing, retarding and/or combating the signs of ageing of the skin.
Type:
Grant
Filed:
August 8, 2019
Date of Patent:
January 4, 2022
Assignee:
SOCIETE DE RECHERCHE COSMETIQUE S.A.R.L.
Abstract: This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, a pharmaceutically acceptable salt thereof, or a combination therefore that can be administered to a human subject in need thereof in a supine position. The disclosure also provides pharmaceutical compositions which can be administered once-a-day. This disclosure further provides pharmaceutical compositions comprising an extended release composition and providing a delayed release period between about 30 min to about 12 hours.
Abstract: A solid state, oil gel composition for keratinous substance, such as skin, contains (a) at least one fatty acid-based gelling agent; (b) at least one polysaccharide fatty acid ester; and (c) at least one oil. An embodiment according to the present invention provides improved storage stability, morphological stability, and application property.
Abstract: Provided is a use of a Macaranga tanarius preparation or extract for manufacturing a composition for enhancing immunity of an insect, particularly a bee. Also provided is a method for enhancing immunity of an insect, particularly a bee. The method comprises administering an effective amount of a composition of the present invention to the insect.
Abstract: The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.
Type:
Grant
Filed:
September 23, 2019
Date of Patent:
November 9, 2021
Assignee:
ELLODI PHARMACEUTICALS, L.P.
Inventors:
Michael A. Gosselin, Jin-Wang Lai, Gopi M. Venkatesh
Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
Abstract: The invention relates to a method for producing an osteoinductive calcium phosphate material, the method comprising the steps of providing a sintered calcium phosphate starting material having a surface topography consisting of calcium phosphate grains, subjecting the sintered calcium phosphate starting material to a hydrothermal treatment of between 125-150° C. for a duration sufficient to change calcium phosphate grains on the surface of the starting material into calcium phosphate needles.
Type:
Grant
Filed:
December 23, 2019
Date of Patent:
October 19, 2021
Assignee:
KUROS BIOSCIENCES B.V.
Inventors:
Florence De Groot-Barrere, Vincent Van Miegem, Huipin Yuan, Joost De Bruijn
Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.
Type:
Grant
Filed:
June 17, 2016
Date of Patent:
October 19, 2021
Assignee:
ESTETRA SPRL
Inventors:
Séverine Francine Isabelle Jaspart, Johannes Jan Platteeuw, Denny Johan Marijn Van Den Heuvel
Abstract: The disclosed technology relates to a composition comprising: 0.1 to 3 wt % (or 0.5 to 2.5 wt %) of a beta hydroxy acid, 0.05 to 3 wt % (or 0.09 to 2.5 wt %) of an O-substituted ascorbic acid or a derivative thereof, and a cosmetically acceptable medium comprising an aqueous phase, wherein a beta hydroxy acid is present at a higher concentration than O-substituted ascorbic acid or a derivative thereof. The disclosed technology further relates to the use and method of improving skin condition.
Type:
Grant
Filed:
June 28, 2017
Date of Patent:
October 5, 2021
Assignee:
THE BOOTS COMPANY PLC
Inventors:
Jake Thomas Hicks, Paul James Tomlinson
Abstract: The invention relates to a surface-modified effect pigment comprising particular additives and to the production thereof. The present invention further provides a nail varnish composition comprising a) at least one effect pigment that has been surface-modified with a starting material (additive), where the effect pigment comprises a substrate in platelet form and optionally at least one coating applied to the substrate, b) at least one hydrocarbon resin as binder, and c) at least one solvent or solvent mixture, where the starting material (additive) for surface modification of the effect pigment is at least one compound taken from the group consisting of phosphoric ester-containing, phosphonic ester-containing, phosphonic acid-containing, fatty acid-containing and/or silane-containing compounds or mixtures thereof.
Type:
Grant
Filed:
April 13, 2017
Date of Patent:
September 7, 2021
Assignee:
ECKART GmbH
Inventors:
Christine Schilling, Ulrich Schmidt, Christina Pippinger, Ann-Katrin Gebhard
Abstract: An antimicrobial eyelid cleanser composition contains: (a) a hypohalous acid; (b) one or more surfactants having a HLB value of 5 to 18; and (c) an aqueous vehicle, the aqueous vehicle comprising: (i) one or more tonicity adjusters; (ii) one or more osmolality adjusters for adjusting an osmolality of the composition; and (iii) one or more pH adjusters for maintaining the pH of the composition at between about 4.5 to about 8.0. The composition can be dispensed in a foam, liquid, spray, mist, gel or lotion form. The composition can facilitate long term eyelid hygiene by removing excess oil, debris and desquamated skin and provide relief for inflammation of the eyes.
Type:
Grant
Filed:
May 1, 2019
Date of Patent:
August 17, 2021
Assignee:
OCUSOFT, INC.
Inventors:
Nat Adkins, Jr., Cynthia Barratt, Thomas Mason, Paramita Sarkar